Oncology/Hematology Market Research Reports & Industry Analysis
Oncology/Hematology Industry Research & Market Reports
-
Malignant Mesothelioma
... CAGR of 6.2% over the analysis period 2024-2030. Premetrexed & Combination, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$518.6 Million by the end of the ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Endometrial Cancer Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$31.3 Billion by the end of the ... Read More
-
Breast Cancer Screening
... at a CAGR of 5.1% over the analysis period 2024-2030. Imaging Test, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.8 Billion by the end of ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage B-cell Lymphoma: Understanding B-cell Lymphoma: Overview ... Read More
-
Metastatic Colorectal Cancer - Pipeline Insight, 2025
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Metastatic Colorectal Cancer: ... Read More
-
2025 Global Gene Therapy For Ovarian Cancer Market Industry (2031 Outlook)
... size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for 46 countries. The report also features written analysis on market definitions, market segments, market ... Read More
-
Next Generation Cancer Diagnostics
... 2030, growing at a CAGR of 21.8% over the analysis period 2024-2030. qPCR & Multiplexing, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$28.2 Billion by ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of the ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More
-
Oncology Nutrition
... CAGR of 9.6% over the analysis period 2024-2030. Head & Neck, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$609.6 Million by the end of the ... Read More
-
Liver Cancer Diagnostics
... at a CAGR of 7.4% over the analysis period 2024-2030. Laboratory Tests, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$9.8 Billion by the end of ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Cancer Cachexia Global Market Report 2025
... is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective with the ... Read More
-
Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025
... cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain ... Read More
-
Non-Melanoma Skin Cancer
... at a CAGR of 4.4% over the analysis period 2024-2030. Basal Cell Carcinoma (BCC), one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$835.6 Million by the ... Read More
-
Kaposi Sarcoma
... CAGR of 3.2% over the analysis period 2024-2030. HAART, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$101.5 Million by the end of the analysis period. ... Read More
-
Immuno-Oncology
... 16.2% over the analysis period 2024-2030. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is expected to record a 16.2% CAGR and reach US$75.1 Billion by the end of the analysis period. ... Read More
-
Veterinary Oncology
... CAGR of 10.9% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 12.0% CAGR and reach US$246.0 Million by the end of the analysis period. ... Read More
-
Urothelial Cancer Drugs
... at a CAGR of 20.7% over the analysis period 2024-2030. Immunotherapy, one of the segments analyzed in the report, is expected to record a 20.3% CAGR and reach US$13.3 Billion by the end of the ... Read More
-
Liver Cancer Drugs
... at a CAGR of 18.4% over the analysis period 2024-2030. Targeted Drug Therapy, one of the segments analyzed in the report, is expected to record a 18.4% CAGR and reach US$5.1 Billion by the end ... Read More
-
Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2025-2033
... 2025-2033. The increasing prevalence of the disease, advancements in personalized medicine, the emergence of new therapies, higher healthcare spending, and growing public awareness about prostate health and available treatment options are strengthening the market growth. ... Read More
-
Biomarkers Market Report by Product (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease (Cancer, Cardiovascular Disorders, Neurological Disorders, Immunological Disorders, Renal Disorders, and Others), Application (Diagnostics, Drug Discovery and Development, Personalized Medicine, and Others), End User (Pharmaceutical and Biotechnology Companies, Diagnostic and Research Laboratories, Hospitals and Specialty Clinics, and Others), and Region 2025-2033
... rising prevalence of chronic diseases, ongoing developments in biotechnology and genomics, the shift toward personalized medicine, continuous advancements in analytical technologies, and increasing awareness among both healthcare professionals and patients about the benefits of biomarkers ... Read More
-
Prostate Cancer Therapeutics
... at a CAGR of 6.6% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$21.0 Billion by the end of ... Read More
-
Bulk Paclitaxel
... CAGR of 8.5% over the analysis period 2024-2030. Semi-Synthetic Paclitaxel API, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$139.1 Million by the end of the ... Read More
Research Assistance
